HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Kits, Software), Application (Antibody Screening), Type (Organ Transplant, Tissue), End User, and Region - Global Forecast to 2028
The global HLA typing for the transplants market is expected to reach USD 1.1 billion by 2028 from USD 0.8 billion in 2023, at a CAGR of 6.3%. Rising technological advancements in the field of HLA typing, increasing demand for transplantation, rising initiatives by the government to boost the organ donation, and increasing research activities in field of HLA typing to support the market growth.
“The independent reference laboratories segment accounted for the largest share of the HLA typing for transplants market, by end-user, in 2022.”
Based on end user, the HLA typing for transplants market is segmented into hospitals & transplant centers, independent reference laboratories, and research laboratories & academic institutes. In 2022, independent reference laboratories accounted for the largest share of the HLA typing for transplants . This is attributed the growing preference of diagnostic laboratories to outsource the HLA typing services by biotechnology companies, presence of high resolution molecular technology , and increasing collaboration among reference laboratories and transplant centers
“The molecular assay technologies segment accounted for the largest share of the HLA typing for transplants market, by technology, in 2022.”
The HLA typing for transplants market, by technology, is segmented into non-molecular and molecular assay technologies. In 2022, the molecular assay technologies segment accounted for the largest share of the HLA typing for transplants market. This is attributed to the strong adoption of molecular technology for HLA typing among end user setting and strong focus of manufacturers towards the development of high resolution assays for the molecular technologies
“North America accounted for the largest share of the HLA typing for transplants market in 2022.”
North America accounted for the largest share of the HLA typing for transplants market in 2022, followed by Europe. This can primarily be availability of advanced diagnostic technology, increased presence of manufacturers, and well established healthcare infrastructure.
Additionally, presence of prominent biotechnology companies engaged in the research of new HLA alleles, increasing transplantation rates, and favorable reimbursement policy to support the growth of market in the region
Breakdown of supply-side primary interviews:
Research Coverage
This report studies the HLA typing for transplants market based on product& service, technology, transplant type, application, end-user, and region. It studies major factors (such as drivers and restraints) affecting market growth. The report also analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. It the the with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.
This report provides insights on the following pointers:
“The independent reference laboratories segment accounted for the largest share of the HLA typing for transplants market, by end-user, in 2022.”
Based on end user, the HLA typing for transplants market is segmented into hospitals & transplant centers, independent reference laboratories, and research laboratories & academic institutes. In 2022, independent reference laboratories accounted for the largest share of the HLA typing for transplants . This is attributed the growing preference of diagnostic laboratories to outsource the HLA typing services by biotechnology companies, presence of high resolution molecular technology , and increasing collaboration among reference laboratories and transplant centers
“The molecular assay technologies segment accounted for the largest share of the HLA typing for transplants market, by technology, in 2022.”
The HLA typing for transplants market, by technology, is segmented into non-molecular and molecular assay technologies. In 2022, the molecular assay technologies segment accounted for the largest share of the HLA typing for transplants market. This is attributed to the strong adoption of molecular technology for HLA typing among end user setting and strong focus of manufacturers towards the development of high resolution assays for the molecular technologies
“North America accounted for the largest share of the HLA typing for transplants market in 2022.”
North America accounted for the largest share of the HLA typing for transplants market in 2022, followed by Europe. This can primarily be availability of advanced diagnostic technology, increased presence of manufacturers, and well established healthcare infrastructure.
Additionally, presence of prominent biotechnology companies engaged in the research of new HLA alleles, increasing transplantation rates, and favorable reimbursement policy to support the growth of market in the region
Breakdown of supply-side primary interviews:
- By Company Type: Tier 1 (48%), Tier 2 (36%), and Tier 3 (16%)
- By Designation: C-level (10%), Director-level (14%), and Others (76%)
- By Region: North America (40%), Europe (32%), APAC (20%), Latin America (5%) and MEA (3%)
Research Coverage
This report studies the HLA typing for transplants market based on product& service, technology, transplant type, application, end-user, and region. It studies major factors (such as drivers and restraints) affecting market growth. The report also analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. It the the with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.
This report provides insights on the following pointers:
- Analysis of key drivers ( increasing transplantation rates, growing technological advancements, increasing government initiatives to boost HLA typing services in transplantation) restraints (high cost of molecular test use in HLA typing procedures), opportunities (technological shift from non-molecular serological assay to molecular assay, high growth offered by emerging markets), and challenges (Significant gap between number of organ donors and transplant recipients) influencing the growth of HLA typing for transplant market
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the HLA typing for transplant market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the HLA typing for transplant market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the HLA typing for transplant market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 KEY STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.6 RECESSION IMPACT: HLA TYPING FOR TRANSPLANTS MARKET
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key data from primary sources
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 GLOBAL HLA TYPING FOR TRANSPLANTS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION METHODOLOGY
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 PROCEDURE-BASED MARKET ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION: HLA TYPING FOR TRANSPLANTS MARKET
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS
2.4.1 RESEARCH ASSUMPTIONS
2.4.2 RESEARCH LIMITATIONS
2.5 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
3 EXECUTIVE SUMMARY
FIGURE 7 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY PRODUCT & SERVICE, 2023 VS. 2028
FIGURE 8 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 9 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 10 HLA TYPING FOR TRANSPLANTS MARKET: GEOGRAPHIC SNAPSHOT (2022)
4 PREMIUM INSIGHTS
4.1 HLA TYPING FOR TRANSPLANTS MARKET OVERVIEW
FIGURE 11 INCREASING NUMBER OF TRANSPLANT PROCEDURES TO DRIVE MARKET
4.2 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY PRODUCT & SERVICE & COUNTRY (2022)
FIGURE 12 REAGENTS & CONSUMABLES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.3 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 13 MOLECULAR ASSAY TECHNOLOGIES SEGMENT TO RETAIN DOMINANCE TILL 2028
4.4 MOLECULAR ASSAY TECHNOLOGIES MARKET, 2023 VS. 2028
FIGURE 14 NGS TO REGISTER HIGHEST GROWTH
4.5 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 15 INDEPENDENT REFERENCE LABORATORY SEGMENT TO DOMINATE MARKET TILL 2028
4.6 HLA TYPING FOR TRANSPLANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 16 CHINA TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 HLA TYPING FOR TRANSPLANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing number of transplant procedures globally
5.2.1.2 Technological advancements in HLA typing
5.2.1.3 Government initiatives to boost HLA typing services in transplantation
5.2.2 RESTRAINTS
5.2.2.1 High cost of molecular tests used for HLA typing
TABLE 2 COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS IN EUROPE (AS OF 2022)
5.2.2.2 Limited reimbursements for target procedures in emerging countries
5.2.3 OPPORTUNITIES
5.2.3.1 Rising adoption of cross-matching and chimerism testing pre/post-transplantation
5.2.3.2 Technological shift from non-molecular serological assays to gene-based HLA profiling
5.2.4 CHALLENGES
5.2.4.1 Significant gap in organ demand and supply
5.3 PRICING ANALYSIS
5.3.1 INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS
TABLE 3 INDICATIVE PRICING FOR HLA TYPING INSTRUMENTS, REAGENTS, AND KITS FOR TRANSPLANTATION
5.3.2 AVERAGE SELLING PRICE OF HLA TYPING INSTRUMENTS, BY KEY PLAYER
TABLE 4 AVERAGE SELLING PRICE OF HLA TYPING FOR TRANSPLANT PRODUCTS
5.4 PATENT ANALYSIS
FIGURE 18 PATENT ANALYSIS OF NEXT-GENERATION SEQUENCING TECHNOLOGIES
5.5 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS OF HLA TYPING FOR TRANSPLANTS MARKET: MAJOR VALUE-ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 20 HLA TYPING FOR TRANSPLANTS MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM MAPPING
FIGURE 21 HLA TYPING FOR TRANSPLANTS MARKET: ECOSYSTEM MAP
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 HLA TYPING FOR TRANSPLANTS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 DEGREE OF COMPETITION
5.9 REIMBURSEMENT SCENARIO
TABLE 6 CPT CODES FOR MOLECULAR DIAGNOSTICS: HLA TESTING FOR TRANSPLANT HISTOCOMPATIBILITY
5.10 REGULATORY LANDSCAPE
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.1 NORTH AMERICA
5.10.1.1 US
5.10.1.2 Canada
5.10.2 EUROPE
5.10.3 ASIA PACIFIC
5.10.3.1 China
5.10.3.2 Japan
TABLE 11 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.10.3.3 India
5.10.4 LATIN AMERICA
5.10.4.1 Brazil
5.10.5 MIDDLE EAST
5.11 KEY CONFERENCES & EVENTS, 2023–2025
TABLE 12 HLA TYPING FOR TRANSPLANTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2023–2025
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 22 REVENUE SHIFT IN HLA TYPING FOR TRANSPLANTS MARKET
5.13 TRADE ANALYSIS
5.13.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 13 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 14 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MARKET PRODUCTS
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MARKET PRODUCTS (%)
5.14.2 BUYING CRITERIA
FIGURE 24 KEY BUYING CRITERIA FOR MARKET PRODUCTS
TABLE 16 KEY BUYING CRITERIA FOR HLA TYPING FOR MARKET PRODUCTS
6 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 17 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
6.2 REAGENTS & CONSUMABLES
6.2.1 REAGENTS & CONSUMABLES TO HOLD LARGEST MARKET SHARE
TABLE 18 HLA TYPING REAGENTS & CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 ADVANCEMENTS IN HLA-BASED GENOME PROFILING TO SUPPORT SEGMENT GROWTH
TABLE 19 HLA TYPING INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.4 SOFTWARE & SERVICES
6.4.1 RISING DEMAND FOR INNOVATIVE SOFTWARE TO DRIVE MARKET
TABLE 20 HLA TYPING SOFTWARE & SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
7 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 21 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 MOLECULAR ASSAY TECHNOLOGIES
TABLE 22 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 23 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.1 PCR-BASED MOLECULAR ASSAYS
TABLE 24 PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 25 PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.1.1 Sequence-specific primer-PCR
7.2.1.1.1 Growing public-private investments in research to support market growth
TABLE 26 SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.1.2 Sequence-specific oligonucleotide-PCR
7.2.1.2.1 Growing awareness of benefits among medical professionals to drive demand
TABLE 27 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.1.3 Real-time PCR
7.2.1.3.1 High cost of real-time PCR and procedural complexity to hamper market growth
TABLE 28 REAL-TIME PCR MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.1.4 Other PCR-based molecular assays
TABLE 29 OTHER PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS
TABLE 30 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 31 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.2.1 Sanger sequencing
7.2.2.1.1 Growing demand for high-throughput DNA sequencers to drive market
TABLE 32 SANGER SEQUENCING MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.2.2 NGS
7.2.2.2.1 High scalability, low turnaround time, and other advantages to boost adoption
TABLE 33 NGS MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.2.3 Other sequencing-based molecular assays
TABLE 34 OTHER SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION)
7.3 NON-MOLECULAR ASSAY TECHNOLOGIES
7.3.1 REPLACEMENT OF NON-MOLECULAR TECHNIQUES WITH DNA-BASED HLA TYPING TO HAMPER MARKET GROWTH
TABLE 35 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)
8 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 36 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
8.2 DIAGNOSTIC APPLICATIONS
TABLE 37 HLA TYPING FOR TRANSPLANTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 38 HLA TYPING FOR TRANSPLANTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
8.2.1 ANTIBODY SCREENING
8.2.1.1 Rising number of recipients for transplant procedures to drive market growth
TABLE 39 ANTIBODY SCREENING MARKET, BY REGION, 2021–2028 (USD MILLION)
8.2.2 CHIMERISM MONITORING
8.2.2.1 Rising trend of personalized transplant medicine for effective risk management to support market growth
TABLE 40 CHIMERISM MONITORING MARKET, BY REGION, 2021–2028 (USD MILLION)
8.2.3 OTHER APPLICATIONS
TABLE 41 OTHER DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
8.3 RESEARCH APPLICATIONS
8.3.1 RISING INVESTMENTS AND SUPPORT FOR RESEARCH TO DRIVE MARKET
TABLE 42 HLA TYPING FOR TRANSPLANTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
9 HLA TYPING FOR TRANSPLANTS MARKET, BY TRANSPLANT TYPE
9.1 INTRODUCTION
TABLE 43 HLA TYPING FOR TRANSPLANTS MARKET, BY TRANSPLANT TYPE, 2021–2028 (USD MILLION)
9.2 SOLID ORGAN TRANSPLANTS
9.2.1 SOLID ORGAN TRANSPLANTS TO HOLD LARGEST MARKET SHARE
TABLE 44 HLA TYPING FOR SOLID ORGAN TRANSPLANTS MARKET, BY REGION, 2021–2028 (USD MILLION)
9.3 SOFT TISSUE TRANSPLANTS
9.3.1 INCREASING BLOOD CANCER PREVALENCE TO BOOST DEMAND
TABLE 45 HLA TYPING FOR SOFT TISSUE TRANSPLANTS MARKET, BY REGION, 2021–2028 (USD MILLION)
10 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 46 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2 INDEPENDENT REFERENCE LABORATORIES
10.2.1 INDEPENDENT LABS TO HOLD LARGEST MARKET SHARE
TABLE 47 HLA TYPING FOR TRANSPLANTS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, 2021–2028 (USD MILLION)
10.3 HOSPITALS & TRANSPLANT CENTERS
10.3.1 RISING TRANSPLANT VOLUMES TO DRIVE DEMAND FOR HLA TYPING
TABLE 48 HLA TYPING FOR TRANSPLANTS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, 2021–2028 (USD MILLION)
10.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
10.4.1 RISING RESEARCH ACTIVITY TO DRIVE MARKET
TABLE 49 HLA TYPING FOR TRANSPLANTS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, 2021–2028 (USD MILLION)
11 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 50 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 25 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT
TABLE 51 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 53 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 54 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.2 US
11.2.2.1 US to hold largest market share
FIGURE 26 US: SOLID ORGAN TRANSPLANTATIONS PERFORMED, 2019–2021
TABLE 55 US: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 56 US: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 57 US: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 58 US: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Rising availability of transplant diagnostic products to support market growth
TABLE 59 CANADA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 60 CANADA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 61 CANADA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 62 CANADA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
TABLE 63 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 65 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 66 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.2 GERMANY
11.3.2.1 Germany to dominate European HLA typing for transplants market
TABLE 67 GERMANY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 68 GERMANY: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 69 GERMANY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 70 GERMANY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.3.3 UK
11.3.3.1 Rising number of transplant procedures to drive market
TABLE 71 UK: NUMBER OF ORGAN TRANSPLANTATION PROCEDURES, 2019 VS. 2021
TABLE 72 UK: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 73 UK: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 74 UK: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 75 UK: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Growing adoption of MDx for donor-recipient compatibility testing to support market
TABLE 76 FRANCE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 77 FRANCE: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 78 FRANCE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 79 FRANCE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Increasing solid organ transplantation procedures to drive market
TABLE 80 SPAIN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 81 SPAIN: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 82 SPAIN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 83 SPAIN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.3.6 ITALY
11.3.6.1 Slowdown in Italian healthcare sector to limit market growth
TABLE 84 ITALY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 85 ITALY: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 86 ITALY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 87 ITALY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 88 REST OF EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 89 REST OF EUROPE: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 90 REST OF EUROPE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 91 REST OF EUROPE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 27 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT
TABLE 92 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 93 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 94 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 95 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Healthcare infrastructural improvements to support market growth
TABLE 96 CHINA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 97 CHINA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 98 CHINA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 99 CHINA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Increasing transplantation procedures to drive market
TABLE 100 INDIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 101 INDIA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 102 INDIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 103 INDIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.4.4 JAPAN
11.4.4.1 Significant growth in chronic disease prevalence to support market growth
TABLE 104 JAPAN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 105 JAPAN: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 106 JAPAN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 107 JAPAN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.4.5 AUSTRALIA
11.4.5.1 Rising number of solid organ transplantation procedures to support market growth
TABLE 108 AUSTRALIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 109 AUSTRALIA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 110 AUSTRALIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 111 AUSTRALIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.4.6 SOUTH KOREA
11.4.6.1 Government support and medical coverage for transplantation to drive market
TABLE 112 SOUTH KOREA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 113 SOUTH KOREA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 114 SOUTH KOREA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 115 SOUTH KOREA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.4.7 REST OF ASIA PACIFIC
TABLE 116 REST OF ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 117 REST OF ASIA PACIFIC: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 118 REST OF ASIA PACIFIC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 119 REST OF ASIA PACIFIC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 120 LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 121 LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 122 LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 123 LATIN AMERICA HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.2 BRAZIL
11.5.2.1 Brazil to dominate LATAM market
TABLE 124 BRAZIL: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 125 BRAZIL: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 126 BRAZIL: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 127 BRAZIL: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.5.3 MEXICO
11.5.3.1 Rising medical tourism to drive market
TABLE 128 MEXICO: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 129 MEXICO: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 130 MEXICO: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 131 MEXICO: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.5.4 REST OF LATIN AMERICA
TABLE 132 REST OF LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 133 REST OF LATIN AMERICA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 134 REST OF LATIN AMERICA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 135 REST OF LATIN AMERICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 GOVERNMENT INITIATIVES AND RISING GERIATRIC POPULATION TO SUPPORT ADOPTION
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 136 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 137 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 138 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 28 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HLA TYPING FOR TRANSPLANTS MARKET (2020 TO 2023)
12.3 REVENUE SHARE ANALYSIS (2022)
FIGURE 29 REVENUE ANALYSIS OF TOP FIVE PLAYERS IN HLA TYPING FOR TRANSPLANTS MARKET, 2019–2022 (USD MILLION)
12.4 MARKET RANKING SHARE
FIGURE 30 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 139 HLA TYPING FOR TRANSPLANTS MARKET: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 31 HLA TYPING FOR TRANSPLANTS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
12.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 32 HLA TYPING FOR TRANSPLANTS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (AS OF 2022)
12.7 COMPETITIVE BENCHMARKING
FIGURE 33 COMPANY FOOTPRINT ANALYSIS: TOP FIVE PLAYERS
TABLE 140 PRODUCT & SERVICE FOOTPRINT ANALYSIS (TOP FIVE PLAYERS)
TABLE 141 REGIONAL FOOTPRINT ANALYSIS (TOP FIVE PLAYERS)
TABLE 142 HLA TYPING FOR TRANSPLANTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
12.8 COMPETITIVE SCENARIO
12.8.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
TABLE 143 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS (2020–2023)
12.8.2 DEALS
TABLE 144 KEY DEALS (2020–2023)
13 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
13.1 KEY PLAYERS
13.1.1 THERMO FISHER SCIENTIFIC
TABLE 145 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW
FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2022)
13.1.2 ILLUMINA, INC.
TABLE 146 ILLUMINA, INC.: COMPANY OVERVIEW
FIGURE 35 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
13.1.3 QIAGEN
TABLE 147 QIAGEN: COMPANY OVERVIEW
FIGURE 36 QIAGEN: COMPANY SNAPSHOT (2022)
13.1.4 BIO-RAD LABORATORIES, INC.
TABLE 148 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 37 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
13.1.5 F. HOFFMANN-LA ROCHE LTD.
TABLE 149 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 38 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2022)
13.1.6 CAREDX
TABLE 150 CAREDX: COMPANY OVERVIEW
FIGURE 39 CAREDX: COMPANY SNAPSHOT (2022)
13.1.7 IMMUCOR, INC.
TABLE 151 IMMUCOR, INC.: COMPANY OVERVIEW
13.1.8 LUMINEX CORPORATION (DIASORIN)
TABLE 152 DIASORIN S.P.A: COMPANY OVERVIEW
FIGURE 40 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
13.1.9 TBG DIAGNOSTICS LIMITED
TABLE 153 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
FIGURE 41 TBG DIAGNOSTICS LIMITED: COMPANY SNAPSHOT (2022)
13.1.10 FUJIREBIO
TABLE 154 FUJIREBIO: COMPANY OVERVIEW
13.1.11 OMIXON, INC.
TABLE 155 OMIXON, INC.: COMPANY OVERVIEW
13.1.12 GENDX
TABLE 156 GENDX.: COMPANY OVERVIEW
13.1.13 BAG DIAGNOSTICS GMBH
TABLE 157 BAG DIAGNOSTICS GMBH: COMPANY OVERVIEW
13.1.14 CREATIVE BIOLABS
TABLE 158 CREATIVE BIOLABS: COMPANY OVERVIEW
13.1.15 PACBIO
TABLE 159 PACBIO: COMPANY OVERVIEW
FIGURE 42 PACBIO: COMPANY SNAPSHOT (2022)
13.2 OTHER PLAYERS
13.2.1 HISTOGENETICS LLC
13.2.2 SCISCO GENETICS, INC.
13.2.3 INNO-TRAIN DIAGNOSTIK GMBH
13.2.4 BIONOBIS
13.2.5 QUEST DIAGNOSTICS
13.2.6 SCIENCELL RESEARCH LABORATORIES, INC.
13.2.7 BGI GENOMICS
13.2.8 CEGAT GMBH
13.2.9 PROIMMUNE LTD.
13.2.10 CD GENOMICS
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 KEY STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.6 RECESSION IMPACT: HLA TYPING FOR TRANSPLANTS MARKET
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key data from primary sources
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 GLOBAL HLA TYPING FOR TRANSPLANTS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION METHODOLOGY
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 PROCEDURE-BASED MARKET ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION: HLA TYPING FOR TRANSPLANTS MARKET
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS
2.4.1 RESEARCH ASSUMPTIONS
2.4.2 RESEARCH LIMITATIONS
2.5 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
3 EXECUTIVE SUMMARY
FIGURE 7 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY PRODUCT & SERVICE, 2023 VS. 2028
FIGURE 8 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 9 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 10 HLA TYPING FOR TRANSPLANTS MARKET: GEOGRAPHIC SNAPSHOT (2022)
4 PREMIUM INSIGHTS
4.1 HLA TYPING FOR TRANSPLANTS MARKET OVERVIEW
FIGURE 11 INCREASING NUMBER OF TRANSPLANT PROCEDURES TO DRIVE MARKET
4.2 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY PRODUCT & SERVICE & COUNTRY (2022)
FIGURE 12 REAGENTS & CONSUMABLES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.3 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 13 MOLECULAR ASSAY TECHNOLOGIES SEGMENT TO RETAIN DOMINANCE TILL 2028
4.4 MOLECULAR ASSAY TECHNOLOGIES MARKET, 2023 VS. 2028
FIGURE 14 NGS TO REGISTER HIGHEST GROWTH
4.5 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 15 INDEPENDENT REFERENCE LABORATORY SEGMENT TO DOMINATE MARKET TILL 2028
4.6 HLA TYPING FOR TRANSPLANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 16 CHINA TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 HLA TYPING FOR TRANSPLANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing number of transplant procedures globally
5.2.1.2 Technological advancements in HLA typing
5.2.1.3 Government initiatives to boost HLA typing services in transplantation
5.2.2 RESTRAINTS
5.2.2.1 High cost of molecular tests used for HLA typing
TABLE 2 COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS IN EUROPE (AS OF 2022)
5.2.2.2 Limited reimbursements for target procedures in emerging countries
5.2.3 OPPORTUNITIES
5.2.3.1 Rising adoption of cross-matching and chimerism testing pre/post-transplantation
5.2.3.2 Technological shift from non-molecular serological assays to gene-based HLA profiling
5.2.4 CHALLENGES
5.2.4.1 Significant gap in organ demand and supply
5.3 PRICING ANALYSIS
5.3.1 INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS
TABLE 3 INDICATIVE PRICING FOR HLA TYPING INSTRUMENTS, REAGENTS, AND KITS FOR TRANSPLANTATION
5.3.2 AVERAGE SELLING PRICE OF HLA TYPING INSTRUMENTS, BY KEY PLAYER
TABLE 4 AVERAGE SELLING PRICE OF HLA TYPING FOR TRANSPLANT PRODUCTS
5.4 PATENT ANALYSIS
FIGURE 18 PATENT ANALYSIS OF NEXT-GENERATION SEQUENCING TECHNOLOGIES
5.5 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS OF HLA TYPING FOR TRANSPLANTS MARKET: MAJOR VALUE-ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 20 HLA TYPING FOR TRANSPLANTS MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM MAPPING
FIGURE 21 HLA TYPING FOR TRANSPLANTS MARKET: ECOSYSTEM MAP
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 HLA TYPING FOR TRANSPLANTS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 DEGREE OF COMPETITION
5.9 REIMBURSEMENT SCENARIO
TABLE 6 CPT CODES FOR MOLECULAR DIAGNOSTICS: HLA TESTING FOR TRANSPLANT HISTOCOMPATIBILITY
5.10 REGULATORY LANDSCAPE
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.1 NORTH AMERICA
5.10.1.1 US
5.10.1.2 Canada
5.10.2 EUROPE
5.10.3 ASIA PACIFIC
5.10.3.1 China
5.10.3.2 Japan
TABLE 11 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.10.3.3 India
5.10.4 LATIN AMERICA
5.10.4.1 Brazil
5.10.5 MIDDLE EAST
5.11 KEY CONFERENCES & EVENTS, 2023–2025
TABLE 12 HLA TYPING FOR TRANSPLANTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2023–2025
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 22 REVENUE SHIFT IN HLA TYPING FOR TRANSPLANTS MARKET
5.13 TRADE ANALYSIS
5.13.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 13 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 14 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MARKET PRODUCTS
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MARKET PRODUCTS (%)
5.14.2 BUYING CRITERIA
FIGURE 24 KEY BUYING CRITERIA FOR MARKET PRODUCTS
TABLE 16 KEY BUYING CRITERIA FOR HLA TYPING FOR MARKET PRODUCTS
6 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 17 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
6.2 REAGENTS & CONSUMABLES
6.2.1 REAGENTS & CONSUMABLES TO HOLD LARGEST MARKET SHARE
TABLE 18 HLA TYPING REAGENTS & CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 ADVANCEMENTS IN HLA-BASED GENOME PROFILING TO SUPPORT SEGMENT GROWTH
TABLE 19 HLA TYPING INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.4 SOFTWARE & SERVICES
6.4.1 RISING DEMAND FOR INNOVATIVE SOFTWARE TO DRIVE MARKET
TABLE 20 HLA TYPING SOFTWARE & SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
7 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 21 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 MOLECULAR ASSAY TECHNOLOGIES
TABLE 22 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 23 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.1 PCR-BASED MOLECULAR ASSAYS
TABLE 24 PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 25 PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.1.1 Sequence-specific primer-PCR
7.2.1.1.1 Growing public-private investments in research to support market growth
TABLE 26 SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.1.2 Sequence-specific oligonucleotide-PCR
7.2.1.2.1 Growing awareness of benefits among medical professionals to drive demand
TABLE 27 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.1.3 Real-time PCR
7.2.1.3.1 High cost of real-time PCR and procedural complexity to hamper market growth
TABLE 28 REAL-TIME PCR MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.1.4 Other PCR-based molecular assays
TABLE 29 OTHER PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS
TABLE 30 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 31 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.2.1 Sanger sequencing
7.2.2.1.1 Growing demand for high-throughput DNA sequencers to drive market
TABLE 32 SANGER SEQUENCING MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.2.2 NGS
7.2.2.2.1 High scalability, low turnaround time, and other advantages to boost adoption
TABLE 33 NGS MARKET, BY REGION, 2021–2028 (USD MILLION)
7.2.2.3 Other sequencing-based molecular assays
TABLE 34 OTHER SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION)
7.3 NON-MOLECULAR ASSAY TECHNOLOGIES
7.3.1 REPLACEMENT OF NON-MOLECULAR TECHNIQUES WITH DNA-BASED HLA TYPING TO HAMPER MARKET GROWTH
TABLE 35 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)
8 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 36 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
8.2 DIAGNOSTIC APPLICATIONS
TABLE 37 HLA TYPING FOR TRANSPLANTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 38 HLA TYPING FOR TRANSPLANTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
8.2.1 ANTIBODY SCREENING
8.2.1.1 Rising number of recipients for transplant procedures to drive market growth
TABLE 39 ANTIBODY SCREENING MARKET, BY REGION, 2021–2028 (USD MILLION)
8.2.2 CHIMERISM MONITORING
8.2.2.1 Rising trend of personalized transplant medicine for effective risk management to support market growth
TABLE 40 CHIMERISM MONITORING MARKET, BY REGION, 2021–2028 (USD MILLION)
8.2.3 OTHER APPLICATIONS
TABLE 41 OTHER DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
8.3 RESEARCH APPLICATIONS
8.3.1 RISING INVESTMENTS AND SUPPORT FOR RESEARCH TO DRIVE MARKET
TABLE 42 HLA TYPING FOR TRANSPLANTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
9 HLA TYPING FOR TRANSPLANTS MARKET, BY TRANSPLANT TYPE
9.1 INTRODUCTION
TABLE 43 HLA TYPING FOR TRANSPLANTS MARKET, BY TRANSPLANT TYPE, 2021–2028 (USD MILLION)
9.2 SOLID ORGAN TRANSPLANTS
9.2.1 SOLID ORGAN TRANSPLANTS TO HOLD LARGEST MARKET SHARE
TABLE 44 HLA TYPING FOR SOLID ORGAN TRANSPLANTS MARKET, BY REGION, 2021–2028 (USD MILLION)
9.3 SOFT TISSUE TRANSPLANTS
9.3.1 INCREASING BLOOD CANCER PREVALENCE TO BOOST DEMAND
TABLE 45 HLA TYPING FOR SOFT TISSUE TRANSPLANTS MARKET, BY REGION, 2021–2028 (USD MILLION)
10 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 46 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2 INDEPENDENT REFERENCE LABORATORIES
10.2.1 INDEPENDENT LABS TO HOLD LARGEST MARKET SHARE
TABLE 47 HLA TYPING FOR TRANSPLANTS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, 2021–2028 (USD MILLION)
10.3 HOSPITALS & TRANSPLANT CENTERS
10.3.1 RISING TRANSPLANT VOLUMES TO DRIVE DEMAND FOR HLA TYPING
TABLE 48 HLA TYPING FOR TRANSPLANTS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, 2021–2028 (USD MILLION)
10.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
10.4.1 RISING RESEARCH ACTIVITY TO DRIVE MARKET
TABLE 49 HLA TYPING FOR TRANSPLANTS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, 2021–2028 (USD MILLION)
11 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 50 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 25 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT
TABLE 51 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 53 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 54 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.2 US
11.2.2.1 US to hold largest market share
FIGURE 26 US: SOLID ORGAN TRANSPLANTATIONS PERFORMED, 2019–2021
TABLE 55 US: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 56 US: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 57 US: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 58 US: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Rising availability of transplant diagnostic products to support market growth
TABLE 59 CANADA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 60 CANADA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 61 CANADA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 62 CANADA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
TABLE 63 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 65 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 66 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.2 GERMANY
11.3.2.1 Germany to dominate European HLA typing for transplants market
TABLE 67 GERMANY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 68 GERMANY: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 69 GERMANY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 70 GERMANY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.3.3 UK
11.3.3.1 Rising number of transplant procedures to drive market
TABLE 71 UK: NUMBER OF ORGAN TRANSPLANTATION PROCEDURES, 2019 VS. 2021
TABLE 72 UK: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 73 UK: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 74 UK: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 75 UK: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Growing adoption of MDx for donor-recipient compatibility testing to support market
TABLE 76 FRANCE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 77 FRANCE: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 78 FRANCE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 79 FRANCE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Increasing solid organ transplantation procedures to drive market
TABLE 80 SPAIN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 81 SPAIN: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 82 SPAIN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 83 SPAIN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.3.6 ITALY
11.3.6.1 Slowdown in Italian healthcare sector to limit market growth
TABLE 84 ITALY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 85 ITALY: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 86 ITALY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 87 ITALY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 88 REST OF EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 89 REST OF EUROPE: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 90 REST OF EUROPE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 91 REST OF EUROPE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 27 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT
TABLE 92 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 93 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 94 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 95 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Healthcare infrastructural improvements to support market growth
TABLE 96 CHINA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 97 CHINA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 98 CHINA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 99 CHINA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Increasing transplantation procedures to drive market
TABLE 100 INDIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 101 INDIA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 102 INDIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 103 INDIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.4.4 JAPAN
11.4.4.1 Significant growth in chronic disease prevalence to support market growth
TABLE 104 JAPAN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 105 JAPAN: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 106 JAPAN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 107 JAPAN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.4.5 AUSTRALIA
11.4.5.1 Rising number of solid organ transplantation procedures to support market growth
TABLE 108 AUSTRALIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 109 AUSTRALIA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 110 AUSTRALIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 111 AUSTRALIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.4.6 SOUTH KOREA
11.4.6.1 Government support and medical coverage for transplantation to drive market
TABLE 112 SOUTH KOREA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 113 SOUTH KOREA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 114 SOUTH KOREA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 115 SOUTH KOREA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.4.7 REST OF ASIA PACIFIC
TABLE 116 REST OF ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 117 REST OF ASIA PACIFIC: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 118 REST OF ASIA PACIFIC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 119 REST OF ASIA PACIFIC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 120 LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 121 LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 122 LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 123 LATIN AMERICA HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.2 BRAZIL
11.5.2.1 Brazil to dominate LATAM market
TABLE 124 BRAZIL: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 125 BRAZIL: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 126 BRAZIL: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 127 BRAZIL: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.5.3 MEXICO
11.5.3.1 Rising medical tourism to drive market
TABLE 128 MEXICO: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 129 MEXICO: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 130 MEXICO: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 131 MEXICO: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.5.4 REST OF LATIN AMERICA
TABLE 132 REST OF LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 133 REST OF LATIN AMERICA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 134 REST OF LATIN AMERICA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 135 REST OF LATIN AMERICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 GOVERNMENT INITIATIVES AND RISING GERIATRIC POPULATION TO SUPPORT ADOPTION
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 136 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 137 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 138 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021–2028 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 28 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HLA TYPING FOR TRANSPLANTS MARKET (2020 TO 2023)
12.3 REVENUE SHARE ANALYSIS (2022)
FIGURE 29 REVENUE ANALYSIS OF TOP FIVE PLAYERS IN HLA TYPING FOR TRANSPLANTS MARKET, 2019–2022 (USD MILLION)
12.4 MARKET RANKING SHARE
FIGURE 30 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 139 HLA TYPING FOR TRANSPLANTS MARKET: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 31 HLA TYPING FOR TRANSPLANTS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
12.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 32 HLA TYPING FOR TRANSPLANTS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (AS OF 2022)
12.7 COMPETITIVE BENCHMARKING
FIGURE 33 COMPANY FOOTPRINT ANALYSIS: TOP FIVE PLAYERS
TABLE 140 PRODUCT & SERVICE FOOTPRINT ANALYSIS (TOP FIVE PLAYERS)
TABLE 141 REGIONAL FOOTPRINT ANALYSIS (TOP FIVE PLAYERS)
TABLE 142 HLA TYPING FOR TRANSPLANTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
12.8 COMPETITIVE SCENARIO
12.8.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
TABLE 143 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS (2020–2023)
12.8.2 DEALS
TABLE 144 KEY DEALS (2020–2023)
13 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
13.1 KEY PLAYERS
13.1.1 THERMO FISHER SCIENTIFIC
TABLE 145 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW
FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2022)
13.1.2 ILLUMINA, INC.
TABLE 146 ILLUMINA, INC.: COMPANY OVERVIEW
FIGURE 35 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
13.1.3 QIAGEN
TABLE 147 QIAGEN: COMPANY OVERVIEW
FIGURE 36 QIAGEN: COMPANY SNAPSHOT (2022)
13.1.4 BIO-RAD LABORATORIES, INC.
TABLE 148 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 37 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
13.1.5 F. HOFFMANN-LA ROCHE LTD.
TABLE 149 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 38 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2022)
13.1.6 CAREDX
TABLE 150 CAREDX: COMPANY OVERVIEW
FIGURE 39 CAREDX: COMPANY SNAPSHOT (2022)
13.1.7 IMMUCOR, INC.
TABLE 151 IMMUCOR, INC.: COMPANY OVERVIEW
13.1.8 LUMINEX CORPORATION (DIASORIN)
TABLE 152 DIASORIN S.P.A: COMPANY OVERVIEW
FIGURE 40 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
13.1.9 TBG DIAGNOSTICS LIMITED
TABLE 153 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
FIGURE 41 TBG DIAGNOSTICS LIMITED: COMPANY SNAPSHOT (2022)
13.1.10 FUJIREBIO
TABLE 154 FUJIREBIO: COMPANY OVERVIEW
13.1.11 OMIXON, INC.
TABLE 155 OMIXON, INC.: COMPANY OVERVIEW
13.1.12 GENDX
TABLE 156 GENDX.: COMPANY OVERVIEW
13.1.13 BAG DIAGNOSTICS GMBH
TABLE 157 BAG DIAGNOSTICS GMBH: COMPANY OVERVIEW
13.1.14 CREATIVE BIOLABS
TABLE 158 CREATIVE BIOLABS: COMPANY OVERVIEW
13.1.15 PACBIO
TABLE 159 PACBIO: COMPANY OVERVIEW
FIGURE 42 PACBIO: COMPANY SNAPSHOT (2022)
13.2 OTHER PLAYERS
13.2.1 HISTOGENETICS LLC
13.2.2 SCISCO GENETICS, INC.
13.2.3 INNO-TRAIN DIAGNOSTIK GMBH
13.2.4 BIONOBIS
13.2.5 QUEST DIAGNOSTICS
13.2.6 SCIENCELL RESEARCH LABORATORIES, INC.
13.2.7 BGI GENOMICS
13.2.8 CEGAT GMBH
13.2.9 PROIMMUNE LTD.
13.2.10 CD GENOMICS
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
